Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA, Industry Aim to Further Strengthen Pharma Supply Chain Quality

This article was originally published in The Gold Sheet

Executive Summary

A stronger pharma supply chain is in the works. Key is to put quality on CEO's radar screen. Progress made in supplier auditing, supply chain standard-setting and regulatory guidance development. Methods shared for improving supplier management. Supply chain mapping recommended. A better certificate of analysis. A think tank for signal detection. Improving distribution security and controls. Support for track-and-trace reimbursement incentive.

You may also be interested in...

Global Efforts Intensify In Fight Against Counterfeit Drugs

Regulators and manufacturers worldwide intensify cracking down on the scourge of counterfeit drugs, with APEC launching a toolkit, industry recruiting participants for a shared audit program and WHO warning that the problem is not going away anytime soon. While anti-malarials and -infectives and vaccines continue as prime targets, a new trend is emerging in “well-regulated’ markets of high-priced hepatitis drugs falsified.


When Pfizer's Gerry Migliaccio told the recent PDA/FDA Pharmaceutical Supply Chain workshop that "Quality should not have to give the final approval of discontinuation" when a pharmaceutical company is considering dropping a substandard supplier, he was saying that other organizations, such as procurement or operations, should be willing to step up and make that decision themselves. Due to a transcription error in the June 2010 issue, this statement could be misconstrued to mean other organizations should be allowed to overrule the quality department

McKinsey Survey Highlights Progress, Challenges in Adoption of QbD

Drug manufacturers are adopting QbD but there are exceptions, especially among some generics firms, McKinsey finds in industry survey. The top challenge to further adoption: misalignment between R&D and commercial operations. Second is a lack of belief in the business case. However, the cost turns out to be low and the financial reward high, McKinsey says.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts